Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M. et al, (2007), J Clin Oncol, 25, 2540 - 2545
Immature platelet fraction: Insight into mechanisms of response to treatment in immune thrombocytopenic purpura
Psaila B. et al, (2007), INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 29, 25 - 25
Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial
Bussel JB. et al, (2007), Journal of Supportive Oncology, 5, 66 - 67
Targeting cell cycle kinases and kinesins in anticancer drug development.
Yap TA. et al, (2007), Expert Opin Drug Discov, 2, 539 - 560
Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place.
Olsen S. et al, (2007), Qual Saf Health Care, 16, 40 - 44
Niche-to-niche migration of bone-marrow-derived cells.
Kaplan RN. et al, (2007), Trends Mol Med, 13, 72 - 81
Novel thrombopoietic agents.
Andemariam B. et al, (2007), Hematology Am Soc Hematol Educ Program, 106 - 113
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study
Steward WP. et al, (2007), Annals of Oncology, 18, 1098 - 1103
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond.
Kaplan RN. et al, (2006), Cancer Metastasis Rev, 25, 521 - 529
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H. et al, (2006), Ann Oncol, 17, 1835 - 1841
Insights into therapeutic mechanisms: Measuring immature platelet fraction (IPF) describes response to treatment in immune thrombocytopenic purpura (ITP).
Psaila B. et al, (2006), BLOOD, 108, 319A - 319A
High-risk melanoma with nodal involvement in a young woman.
Khan O. and Middleton M., (2006), Nat Clin Pract Oncol, 3, 517 - 521
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A. et al, (2006), Ann Oncol, 17, 1313 - 1319
Cancer - Identifying and overcoming resistance to treatment - Editorial overview
Kerr D. and Middleton M., (2006), CURRENT OPINION IN PHARMACOLOGY, 6, 321 - 322
Cancer. Identifying and overcoming resistance to treatment
Kerr D. and Middleton M., (2006), Current Opinion in Pharmacology, 6, 321 - 322
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Sabharwal A. and Middleton MR., (2006), Curr Opin Pharmacol, 6, 355 - 363
First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).
Plummer R. et al, (2006), JOURNAL OF CLINICAL ONCOLOGY, 24, 456S - 456S
Phase I study of ATN-224 in patients (pts) with advanced solid tumours.
Lowndes SA. et al, (2006), JOURNAL OF CLINICAL ONCOLOGY, 24, 95S - 95S